Clinical Trial Update: A Multiple Dose Study of ABT-555 in Subjects With Relapsing Forms of Multiple Sclerosis [Phase 1]

View source ↗

Summary

AbbVie conducted a Phase 1 multiple-dose study of ABT-555 in relapsing forms of multiple sclerosis; the trial status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• ABT 555

Snippet

Sponsor: AbbVie | Conditions: Multiple Sclerosis | Phase 1 | Status: COMPLETED